Dr Reddy's launches anti-bacterial drug in US

Available in bottle counts of 30, it is the genreic equivalent of Avelox

Following the approval by the United States Food and Drug Administration (USFDA), Hyderabad-based pharmaceutical major Dr Reddy's Laboratories Limited launched moxifloxacin hydrocloride tablets in 400 mg strength in the US market on March 4, 2014.

Available in bottle counts of 30, Dr Reddy's moxifloxacin hydrocloride drug is an equivalent generic version of Bayer Aktiengesellschaft's Avelox used in the treatment of bacterial infections.

According to IMS Health, the Avelox tablets' brand has US sales of approximately $195 million for the 12 months ending in December 2013, Dr Reddy's said in a press release on Wednesday.

Dr Reddy's share is currently trading at Rs 2,829 on the BSE, up 0.94%, over the previous close of Rs 2,802.55 a share.